Pfizer said its revenue edged lower in the third quarter, hurt by generic competition for several key drugs, while its profit was buoyed by fewer restructuring charges.
from WSJ.com: US Business http://ift.tt/1DW3s1F
via IFTTT
from WSJ.com: US Business http://ift.tt/1DW3s1F
via IFTTT
No comments:
Post a Comment